Tonix Pharmaceuticals
UEI: JYPLHNCHF675
• CAGE: 5LRD9
Overview
Awardee Type
Parent
(1 child)
Company Description
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases.
Name
Tonix Pharmaceuticals
Website
Headquarters
Chatham, NJ
United States
United States
Most Recent Award
Aug. 1, 2024
Calculating
Federal grant recipient
TONIX PHARMACEUTICALS, INC.
(UEI JYPLHNCHF675, CAGE 5LRD9)
is headquartered in Chatham NJ.
Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The corporation
was founded in June 2007 and
federally registered in
July 2009.
Federal Award Analysis
Tonix Pharmaceuticals federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
Legal Name
TONIX PHARMACEUTICALS, INC.
Division Name
TONIX PHARMACEUTICALS INC.
Division Number
TONIX PHAR
UEI
JYPLHNCHF675
CAGE Code
5LRD9
SBA Certifications
None
Self Certifications
None
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
June 7, 2007
Initial Registration
July 30, 2009
Last Registration
Feb. 25, 2025
Registration Activation
Feb. 25, 2025
Registration Expiration
Feb. 21, 2026
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
Manufacturer of Goods
Manufacturer of Goods
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Reported NAICS
Reported PSC
Accepts Credit Cards
No
People
Vendor contacts at Tonix Pharmaceuticals
GSA Schedules and Price Lists
- Tonix Medicines
- PoP: 7/31/24 - 7/31/29
- Tonix Medicines
- PoP: 5/3/24 - 8/1/24 (Ended)